Company Quick10K Filing
Quick10K
Oragenics
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.41 46 $19
10-Q 2019-06-30 Quarter: 2019-06-30
10-Q 2019-03-31 Quarter: 2019-03-31
10-K 2018-12-31 Annual: 2018-12-31
10-Q 2018-09-30 Quarter: 2018-09-30
10-Q 2018-06-30 Quarter: 2018-06-30
10-Q 2018-03-31 Quarter: 2018-03-31
10-K 2017-12-31 Annual: 2017-12-31
10-Q 2017-09-30 Quarter: 2017-09-30
10-Q 2017-06-30 Quarter: 2017-06-30
10-Q 2017-03-31 Quarter: 2017-03-31
10-K 2016-12-31 Annual: 2016-12-31
10-Q 2016-09-30 Quarter: 2016-09-30
10-Q 2016-06-30 Quarter: 2016-06-30
10-Q 2016-03-31 Quarter: 2016-03-31
10-K 2015-12-31 Annual: 2015-12-31
10-Q 2015-09-30 Quarter: 2015-09-30
10-Q 2015-06-30 Quarter: 2015-06-30
10-Q 2015-03-31 Quarter: 2015-03-31
10-K 2014-12-31 Annual: 2014-12-31
10-Q 2014-09-30 Quarter: 2014-09-30
10-Q 2014-06-30 Quarter: 2014-06-30
10-Q 2014-03-31 Quarter: 2014-03-31
10-K 2013-12-31 Annual: 2013-12-31
8-K 2019-09-30 Regulation FD, Exhibits
8-K 2019-09-25 Other Events, Exhibits
8-K 2019-09-23 Regulation FD, Exhibits
8-K 2019-09-06 Regulation FD, Exhibits
8-K 2019-06-20 Shareholder Vote, Exhibits
8-K 2019-03-21 Enter Agreement, Other Events, Exhibits
8-K 2019-03-21 Other Events, Exhibits
8-K 2019-03-20 Other Events, Exhibits
8-K 2019-03-15 Other Events, Exhibits
8-K 2019-02-22 Officers
8-K 2018-12-19 Officers
8-K 2018-12-03 Regulation FD, Exhibits
8-K 2018-10-17 Other Events, Exhibits
8-K 2018-10-03 Other Events
8-K 2018-09-27 Officers, Other Events, Exhibits
8-K 2018-09-25 Other Events, Exhibits
8-K 2018-08-15 Regulation FD, Other Events, Exhibits
8-K 2018-07-13 Enter Agreement, Amend Bylaw, Other Events, Exhibits
8-K 2018-06-22 Officers, Amend Bylaw, Shareholder Vote, Exhibits
8-K 2018-06-06 Enter Agreement, Officers, Exhibits
8-K 2018-05-30 Other Events, Exhibits
8-K 2018-05-23 Other Events, Exhibits
8-K 2018-04-06 Enter Agreement, Sale of Shares, Exhibits
8-K 2018-01-19 Shareholder Rights, Amend Bylaw, Exhibits
8-K 2018-01-08 Other Events, Exhibits
BMRN Biomarin Pharmaceutical 13,860
XTLB Xtl Biopharmaceuticals 946
OMER Omeros 912
VRCA Verrica Pharmaceuticals 253
BTAI Bioxcel Therapeutics 157
CAPR Capricor Therapeutics 84
SBPH Spring Bank Pharmaceuticals 66
EQ Embarq 64
VTGN Vistagen Therapeutics 29
KMPH Kempharm 27
OGEN 2019-06-30
Part I - Financial Information
Item 1. Financial Statements
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Item 4. Controls and Procedures
Part II - Other Information
Item 1. Legal Proceedings
Item 1A. Risk Factors
Item 2. Unregistered Sale of Equity Securities and Use of Proceeds
Item 3. Defaults Upon Senior Securities
Item 4. Mine Safety Disclosures
Item 5. Other Information
Item 6. Exhibits
EX-31.1 ogen-ex311_6.htm
EX-31.2 ogen-ex312_8.htm
EX-32.1 ogen-ex321_9.htm
EX-32.2 ogen-ex322_7.htm

Oragenics Earnings 2019-06-30

OGEN 10Q Quarterly Report

Balance SheetIncome StatementCash Flow

10-Q 1 ogen-10q_20190630.htm 10-Q ogen-10q_20190630.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019.

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                  to                 

Commission File Number: 001-32188

 

ORAGENICS, INC.

(Exact name of registrant as specified in its charter)

 

 

FLORIDA

 

59-3410522

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

 

4902 Eisenhower Blvd., Suite 125

Tampa, Florida 33634

(Address of principal executive offices)

813-286-7900

(Issuer’s telephone number)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock

 

OGEN

 

NYSE American

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “accelerated filer”, “large accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer

 

 

Accelerated filer

 

 

 

 

 

 

 

 

Non-accelerated filer

 

  

 

Smaller reporting company

 

 

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

Indicate the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date:

As of August 12, 2019, there were 46,124,803 shares of Common Stock, $.001 par value, outstanding.

 


 

 

 

 

 

Page

PART I – FINANCIAL INFORMATION

 

3

 

 

 

 

 

Item 1.

 

Financial Statements

 

3

 

 

 

 

 

 

 

Balance Sheets as of June 30, 2019 (unaudited) and December 31, 2018

 

3

 

 

 

 

 

 

 

Statements of Operations For the Three and Six Months Ended June 30, 2019 and 2018 (unaudited)

 

4

 

 

 

 

 

 

 

Statements of Cash Flows For the Six Months Ended June 30, 2019 and 2018 (unaudited)

 

5

 

 

 

 

 

 

 

Notes to Financial Statements (unaudited)

 

6

 

 

 

 

 

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

16

 

 

 

 

 

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk.

 

26

 

 

 

 

 

Item 4.

 

Controls and Procedures

 

26

 

 

 

 

 

PART II – OTHER INFORMATION

 

27

 

 

 

Item 1.

 

Legal Proceedings

 

27

 

 

 

 

 

Item 1A.

 

Risk Factors

 

27

 

 

 

 

 

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

 

29

 

 

 

 

 

Item 3.

 

Defaults Upon Senior Securities

 

29

 

 

 

 

 

Item 4.

 

Mine Safety Disclosures

 

29

 

 

 

 

 

Item 5.

 

Other Information

 

29

 

 

 

 

 

Item 6.

 

Exhibits

 

30

 

 

 

 

 

Signatures

 

31

 

2


PART I – FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

Oragenics, Inc.

Balance Sheets

 

 

 

June 30,

2019

 

 

December 31,

2018

 

 

 

(Unaudited)

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

25,719,626

 

 

$

20,208,301

 

Prepaid expenses and other current assets

 

 

355,413

 

 

 

1,724,975

 

Total current assets

 

 

26,075,039

 

 

 

21,933,276

 

Property and equipment, net

 

 

101,585

 

 

 

116,276

 

Operating lease right-of-use assets

 

 

756,337

 

 

 

 

Total assets

 

$

26,932,961

 

 

$

22,049,552

 

Liabilities and Shareholders’ Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

1,741,051

 

 

$

1,043,356

 

Short-term notes payable

 

 

12,526

 

 

 

124,213

 

Operating lease liabilities

 

 

140,327

 

 

 

 

Total current liabilities

 

 

1,893,904

 

 

 

1,167,569

 

 

 

 

 

 

 

 

 

 

Long-term liabilities:

 

 

 

 

 

 

 

 

Operating lease liabilities

 

 

616,157

 

 

 

 

Total long-term liabilities

 

 

616,157

 

 

 

 

 

 

 

 

 

 

 

 

 

Shareholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, no par value; 50,000,000 shares authorized; 9,417,000 and

   9,417,000 Series A shares, 6,600,000 and 6,600,000 Series B shares,

   113.941 and 101.733 Series C shares issued and outstanding at

   June 30, 2019 and December 31, 2018, respectively

 

 

6,513,396

 

 

 

6,100,182

 

Common stock, $0.001 par value; 200,000,000 shares authorized; 46,124,803

   and 29,433,135 shares issued and outstanding at June 30, 2019 and

   December 31, 2018, respectively

 

 

46,125

 

 

 

29,433

 

Additional paid-in capital

 

 

137,782,378

 

 

 

126,125,976

 

Accumulated deficit

 

 

(119,918,999

)

 

 

(111,373,608

)

Total shareholders’ equity

 

 

24,422,900

 

 

 

20,881,983

 

Total liabilities and shareholders’ equity

 

$

26,932,961

 

 

$

22,049,552

 

 

See accompanying notes.

3


Oragenics, Inc.

Statements of Operations

(Unaudited)

 

 

 

For the Three Months

Ended June 30,

 

 

For the Six Months

Ended June 30,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

3,879,146

 

 

$

1,271,542

 

 

$

6,292,908

 

 

$

2,597,783

 

General and administrative

 

 

1,025,708

 

 

 

1,012,007

 

 

 

2,006,156

 

 

 

1,807,470

 

Total operating expenses

 

 

4,904,854

 

 

 

2,283,549

 

 

 

8,299,064

 

 

 

4,405,253

 

Loss from operations

 

 

(4,904,854

)

 

 

(2,283,549

)

 

 

(8,299,064

)

 

 

(4,405,253

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

99,427

 

 

 

3,254

 

 

 

169,517

 

 

 

6,728

 

Interest expense

 

 

(733

)

 

 

(664

)

 

 

(2,030

)

 

 

(1,501

)

Local business tax

 

 

(300

)

 

 

(330

)

 

 

(600

)

 

 

(660

)

Total other income, net

 

 

98,394

 

 

 

2,260

 

 

 

166,887

 

 

 

4,567

 

Loss before income taxes

 

 

(4,806,460

)

 

 

(2,281,289

)

 

 

(8,132,177

)

 

 

(4,400,686

)

Income tax benefit

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(4,806,460

)

 

$

(2,281,289

)

 

$

(8,132,177

)

 

$

(4,400,686

)

Basic and diluted net loss per share

 

$

(0.10

)

 

$

(0.38

)

 

$

(0.21

)

 

$

(0.80

)

Shares used to compute basic and diluted net loss per share

 

 

46,120,545

 

 

 

6,028,701

 

 

 

38,330,274

 

 

 

5,509,741

 

See accompanying notes.

4


Oragenics, Inc.

Statements of Cash Flows

(Unaudited)

 

 

 

For the Six Months

Ended June 30,

 

 

 

2019

 

 

2018

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(8,132,177

)

 

$

(4,400,686

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

26,192

 

 

 

11,016

 

Stock issued as compensation to non-employee directors

 

 

 

 

 

24,320

 

Stock-based compensation expense

 

 

310,417

 

 

 

200,310

 

Stock issued in exchange for services

 

 

12,001

 

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

 

1,387,250

 

 

 

(201,496

)

Accounts payable and accrued expenses

 

 

697,695

 

 

 

719,077

 

Net cash used in operating activities

 

 

(5,698,622

)

 

 

(3,647,459

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchase of property and equipment

 

 

(11,354

)

 

 

 

Net cash used in investing activities

 

 

(11,354

)

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Payments on short-term notes payable

 

 

(129,375

)

 

 

(88,481

)

Net proceeds from issuance of common stock and warrants

 

 

11,350,676

 

 

 

1,510,327

 

Net cash provided by financing activities

 

 

11,221,301

 

 

 

1,421,846

 

Net increase (decrease) in cash and cash equivalents

 

 

5,511,325

 

 

 

(2,225,613

)

Cash and cash equivalents at beginning of period

 

 

20,208,301

 

 

 

6,166,143

 

Cash and cash equivalents at end of period

 

$

25,719,626

 

 

$

3,940,530

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

 

 

Interest paid

 

$

2,045

 

 

$

1,501

 

Non-cash investing and financing activities:

 

 

 

 

 

 

 

 

Borrowings under short term notes payable for prepaid expense

 

$

17,688

 

 

$

28,915

 

Par value of restricted stock issued

 

 

 

 

$

16

 

Stock dividend on Series C preferred stock

 

$

413,215

 

 

$

58,670

 

Par value of common stock issued in connection with Series A Preferred

   Stock Conversion

 

 

 

 

$

259

 

Value of Series A preferred stock converted into common stock

 

 

 

 

$

268,096

 

Par value of common stock issued in exchange for services

 

$

25

 

 

 

 

 

See accompanying notes.

5


Oragenics, Inc.

Notes to Financial Statements

(Unaudited)

1. Organization

Oragenics, Inc. (formerly known as Oragen, Inc.) (the “Company” or “we”) was incorporated in November, 1996. We are focused on becoming a leader in developing novel antibiotics against infectious disease and on developing effective treatments for oral mucositis.

2. Basis of Presentation

The accompanying unaudited interim financial statements as of June 30, 2019 and December 31, 2018 (audited) and three and six months ended June 30, 2019 and 2018 have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. In the opinion of management, the accompanying financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the financial condition, results of operations and cash flows for the periods presented. The results of operations for the interim period ending June 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019 or any future period.

These financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2018, which are included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 29, 2019. The Company has incurred recurring losses and negative cash flows from operations since inception. To date, the Company has not generated significant revenues from operations. The Company incurred a net loss of $8,132,177 and used cash of $5,698,622 in its operating activities during the six months ended June 30, 2019. As of June 30, 2019, the Company had an accumulated deficit of $119,918,999.

The Company expects to incur substantial expenditures to further develop each of its technologies. The Company believes the working capital at June 30, 2019 will be sufficient to meet the business objectives, as presently structured, through the fourth quarter of 2020. As such, there is substantial doubt that we can continue as a going concern beyond that date.

The Company’s ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing or achieve profitable operations, as to which no assurances can be given. Cash requirements may vary materially from those now planned because of changes in the Company’s focus and direction of its research and development programs, competitive and technical advances, or other developments. Additional financing will be required to continue operations after the Company exhausts its current cash resources and to continue its long-term plans for clinical trials and new product development. There can be no assurance that any such financing can be realized by the Company, or if realized, what the terms thereof may be, or that any amount that the Company is able to raise will be adequate to support the Company’s working capital requirements until it achieves profitable operations.

The Company intends to seek additional funding through sublicensing arrangements, joint venturing or partnering, sales of rights to technology, government grants and public or private financings. The Company’s future success depends on its ability to raise capital and ultimately generate revenue and attain profitability. The Company cannot be certain that additional capital, whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to it or, if available, will be on terms acceptable to the Company. If the Company issues additional securities to raise funds, these securities may have rights, preferences, or privileges senior to those of its common stock, and the Company’s current shareholders may experience dilution. If the Company is unable to obtain funds when needed, or on acceptable terms, the Company may be required to curtail its current development programs, cut operating costs, and forego future development and other opportunities.

6


3. Significant Accounting Policies

Recently Issued Accounting Pronouncements

In July 2018, the Financial Accounting Standards Board issued Accounting Standards Updates 2018-10 Codification Improvements to Topic 842, Leases and 2018-11 Leases (Topic 842).

Update 2018-10 Codification Improvements to Topic 842 represent changes to clarify the Codification, correct unintended application of guidance, or make minor improvements to the Codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. Some of the amendments make the Codification easier to understand and easier to apply by eliminating inconsistencies, providing needed clarifications, and improving the presentation of guidance in the Codification.

Update 2018-11 Leases (Topic 842) provides entities with an additional (and optional) transition method to adopt the new lease requirements by allowing entities to initially apply the requirements by recognizing a cumulative-effect adjustment transition method, which applies the provisions of the standard at the effective date without adjusting comparative periods presented. Consequently, an entity’s reporting for the comparative periods presented in the financial statements in which the entity adopts the new lease requirements would continue to be in accordance with current GAAP (Topic 840). An entity electing this additional (and optional) transition method must provide the required Topic 840 disclosures for all periods that continue to be in accordance with Topic 840. The amendments do not change the existing disclosure requirements in Topic 840. We implemented this standard on January 1, 2019 using the cumulative-effect adjustment transition method, which applies the provisions of the standard at the effective date without adjusting the comparative periods presented. The Company adopted the following practical expedients and elected the following accounting policies related to this standard:

 

We did not reassess whether any expired or existing contracts are or contain leases.

 

We did not reassess the lease classification for any expired or existing leases.

 

We did not reassess initial direct costs for any existing leases.

The standard did not have a material impact on our balance sheets or on our statements of operations. The most significant impact was the recognition of right of use (ROU) assets and lease liabilities for operating leases. We implemented internal controls to enable the preparation of financial information on adoption of the standard. Adoption of the lease standard had no impact to cash provided by or used in operating, financing, or investing activities in the cash flow statements.

In June 2018, the Financial Accounting Standards Board issued Accounting Standards Update 2018-07 Compensation—Stock Compensation (Topic 718) Improvements to Nonemployee Share-Based Payment Accounting. The amendments in this Update expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The requirements of Topic 718 should be applied to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers.

The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The adoption of this guidance did not have a material impact on the Company’s results of operation, financial position or disclosures.

There are no additional accounting pronouncements issued or effective during the three and six months ended June 30, 2019 that have had, or are expected to have, a material impact on our financial statements.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The principal areas of estimation reflected in the financial statements are stock based compensation, valuation of warrants, and income tax valuation allowance.

Stock-Based Payment Arrangements

Generally, all forms of stock-based payments, including stock option grants, warrants, and restricted stock grants are measured at their fair value on the awards’ grant date using a Black-Scholes pricing model. Stock-based compensation awards issued to non-employees for services rendered are recorded at the fair value of the stock-based payment. The expense resulting from stock-based payments are recorded in research and development expense or general and administrative expense in the

7


statement of operations, depending on the nature of the services provided. Stock-based payment expense is recorded over the requisite service period in which the grantee provides services to the Company. To the extent the stock option grants, warrants, or restricted stock grants do not vest at the grant date they are subject to forfeiture.

Stock-Based Compensation

US GAAP requires all stock-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values as of the grant date. Stock-based compensation expense is recorded over the requisite service period in which the grantee provides services to the Company, to the extent the options do not vest at the grant date and are subject to forfeiture. For performance-based awards that do not include market-based conditions, we record share-based compensation expense only when the performance-based milestone is deemed probable of achievement. We utilize both quantitative and qualitative criteria to judge whether milestones are probable of achievement. For awards with market-based performance conditions, we recognize the grant-date fair value of the award over the derived service period regardless of whether the underlying performance condition is met. In connection with adopting ASU 2016-09, the Company made an accounting policy election to account for forfeitures in compensation expense as they occur.

Warrants

The Company used the Black Scholes Option Pricing Model in calculating the relative fair value of any warrants that have been issued.

Net Loss Per Share

During all periods presented, the Company had securities outstanding that could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted net loss per share, as their effect would have been antidilutive because the Company reported a net loss for all periods presented. Basic and diluted net loss per share amounts are the same for the periods presented. Net loss per share is computed using the weighted average number of shares of common stock outstanding.

Concentrations

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. As of June 30, 2019 and December 31, 2018, the uninsured portion of this balance was $25,469,626 and $19,958,301, respectively.

4. Stock-based Compensation

The Company recognized stock-based compensation on all employee and non-employee awards as follows:

 

 

 

For the Three Months Ended June 30, 2019

 

 

For the Three Months Ended June 30, 2018

 

 

For the Six Months Ended June 30, 2019

 

 

For the Six Months Ended June 30, 2018

 

Research and development

 

$

35,784

 

 

$

9,192

 

 

$

72,087

 

 

$

18,048

 

General and administrative

 

 

128,804

 

 

 

97,114

 

 

 

238,330

 

 

 

206,582

 

Total Stock-based compensation

 

$

164,588

 

 

$

106,306

 

 

$

310,417

 

 

$

224,630

 

 

At the Company’s Annual Meeting of Shareholders, held on June 20, 2019, the shareholders approved an amendment to the Company’s 2012 Equity Incentive Plan (the “Plan”) solely to increase the common shares available for awards thereunder by an additional 6,000,000 shares and ratified an amendment approved by shareholders at the prior year’s annual meeting to increase the shares available under the Plan by 1,500,000 shares. The aggregate number of shares of the Company’s common stock currently authorized pursuant to its Plan, as amended, is 8,250,000 and the Company’s Plan, as amended continues to provide that the maximum number of shares that may be subject to stock options and stock appreciation rights granted to any individual in a calendar year is 1,000,000 shares. The Plan also provides that the maximum number of shares that may be subject to awards (other than stock options and stock appreciation rights) intended to qualify as “performance-based compensation” under Section 162(m) of the Internal Revenue Code that may be granted to any individual in one calendar year is 1,000,000 shares (however, the exception for “performance-based compensation” under Code Section 162(m) was repealed in the Tax Cuts and Jobs Act of 2017, unless the awards intended to qualify for such exception were granted before November 2, 2017). As of June 30, 2019, an aggregate of 2,488,293 shares of common stock are covered by outstanding option awards and 5,520,957 shares of common stock are available for future awards under the Plan.

8


The Company granted 626,160 and 676,160 stock options under its Plan, with a weighted-average grant date fair value of $0.48 and $0.49 per share, during the three and six months ended June 30, 2019. The Company granted 128,000 and 128,000 stock options under its Plan, with a weighted-average grant date fair value of $1.52 and $1.52 per share, during the three and six months ended June 30, 2018.

During the six months ended June 30, 2019, 144,534 stock options previously granted under the Plan have vested, no stock options were forfeited, and no stock options were exercised.

Each executive officer and non-employee director receiving equity-based awards is subject to a minimum dollar value stock ownership holding requirement with respect to the awards received as well as all prior equity awards under the Plan which requirements are intended to align the ability to sell shares with the performance of the Company’s stock price. The executive officer recipients each have a minimum dollar value stock ownership holding requirement threshold equal to two times (2x) their then base salaries below which dollar threshold they would be precluded from selling any shares of Company stock obtained from the Company under its Plan. Also, the non-employee directors are each subject to a minimum dollar value stock ownership holding requirement threshold equal to six times the annual Board retainer ($270,000) below which dollar threshold they would be precluded from selling shares of Company stock acquired from the Company under its Plan.

5. Warrants

On March 25, 2019, the Company announced the closing of an underwritten public offering for gross proceeds of approximately $12.5 million, which included the partial exercise of the underwriter’s over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company.

The offering was comprised of 16,666,668 shares of common stock, together with short-term warrants to purchase up to 8,333,334 shares of common stock, and long-term warrants to purchase up to 8,333,334 shares of common stock, at a price to the public of $0.75. The Company granted the underwriter a 30-day option to purchase up to 2,500,000 additional shares of common stock and/or short-term warrants to purchase 1,250,000 shares of common stock and long-term warrants to purchase 1,250,000 shares of common stock of the Company at the public offering price, less underwriting discounts and commissions. The underwriter exercised its option to purchase the short-term warrants to purchase 1,250,000 shares of common stock and long-term warrants to purchase 1,250,000 shares of common stock effective as of the closing.

Each short-term warrant has an exercise price of $0.75 per share of common stock, is immediately exercisable, and will expire on the earlier of (1) the eighteen-month anniversary of the date of issuance and (2) twenty-one trading days following the Company’s release of top-line data related to its Phase 2 double blind, placebo controlled clinical trial of AG013. Each long-term warrant has an exercise price of $0.90 per share of common stock, is immediately exercisable and will expire five years following the date of issuance.

A summary of warrant activity for the year ended December 31, 2018 and the six months ended June 30, 2019 is as follows:

 

 

 

Warrants

 

 

Weighted

Average

Price

 

Balance - December 31, 2017

 

 

2,177,425

 

 

$

3.10

 

Granted

 

 

14,700,000

 

 

 

1.00

 

Exercised

 

 

(9,505,500

)

 

 

1.00

 

Expired

 

 

 

 

 

 

Balance - December 31, 2018

 

 

7,371,925

 

 

 

1.74

 

Granted

 

 

19,166,668

 

 

 

0.83

 

Exercised

 

 

 

 

 

 

Expired

 

 

 

 

 

 

Balance - June 30, 2019

 

 

26,538,593

 

 

$

1.08

 

 

9


The warrants outstanding as of June 30, 2019 are as follows:

 

 

 

Exercise Price

 

 

Warrants

Outstanding

 

 

Expiration

Date

 

 

$

3.10

 

 

 

48,387

 

 

9/19/2022

 

 

$

2.00

 

 

 

900,000

 

 

4/10/2023

 

 

$

3.10

 

 

 

462,106

 

 

5/10/2024

 

 

$

3.10

 

 

 

602,414

 

 

7/25/2024

 

 

$

3.10

 

 

 

1,064,518

 

 

11/8/2024

 

 

$

1.00

 

 

 

4,294,500

 

 

7/17/2025

 

 

$

0.75

 

 

 

9,583,334

 

 

9/25/2020*

 

 

$

0.90

 

 

 

9,583,334

 

 

3/25/2024

 

 

 

 

 

 

 

26,538,593

 

 

 

 

 

 

 

 

 

 

 

 

 

 

* Subject to termination prior to the indicated date following the Company’s release of top-line data related to its Phase 2 double blind, placebo controlled clinical trial of AG013 plus twenty-one (21) trading days.

 

All outstanding warrants are classified as equity on the Company’s Balance Sheets.

6. Short-Term Notes Payable

As of June 30, 2019 and December 31, 2018, the Company had $12,526 and $124,213, respectively, in short-term notes payable for the financing of various insurance policies.

Products Liability Insurance 

On March 10, 2019, the Company entered into a short-term note payable for $17,688 bearing interest at 5.69% per annum to finance the product liability insurance. Principal and interest payments on this note began April 10, 2019 and are made evenly based on a straight-line amortization over an 11-month period with the final payment being due on February 10, 2020.

On March 10, 2018, the Company entered into a short-term note payable for $28,915 bearing interest at 5.09% per annum to finance the product liability insurance. Principal and interest payments on this note began April 10, 2018 and are made evenly based on a straight-line amortization over an 11-month period with the final payment being made on February 12, 2019.

Directors’ and Officers’ Insurance

On July 24, 2018, the Company entered into a short-term note payable for $215,575 bearing interest at 5.24% to finance a portion of the directors’ and officers’ liability insurance and employment practices liability insurance premiums. Principal and interest payments on this note began August 24, 2018 and were made evenly based on a straight-line amortization over an 11-month period with the final payment being made on June 27, 2019.

7. Commitments and Contingencies

In June 2012, we entered into an Exclusive Channel Collaboration Agreement with Intrexon Corporation (“Intrexon”) for the development and commercialization of the native strain of MU1140 and related homologs using Intrexon’s advanced transgene and cell engineering platforms (the “Lantibiotic ECC”). In June of 2015, we also entered into an Exclusive Channel Collaboration Agreement with Intrexon and Intrexon Actobiotics NV, (a wholly-owned subsidiary of Intrexon), for the continued development and commercialization of AG013, for use in the treatment of oral mucositis in humans through the administration of an effector via genetically modified bacteria, but, in any case, excluding the delivery of anti-cancer effectors for the purpose of treatment or prophylaxis of cancer which was assigned by Intrexon to its wholly owned subsidiary, ActoBio Therapeutics, Inc. (the “Oral Mucositis ECC”). Intrexon Corporation together with its wholly owned subsidiaries are hereinafter collectively referred to as “Intrexon.”

The Lantibiotic ECC

Under the Lantibiotic ECC, and subject to certain exceptions, the Company is responsible for, among other things, funding the further anticipated development of lantibiotics toward the goal of commercialization, conducting nonclinical and clinical development of candidate lantibiotics, as well as for other aspects of manufacturing and the commercialization of the product(s). Among other things, Intrexon is responsible for technology discovery efforts, cell-engineering development, certain aspects of the manufacturing process, and costs of filing, prosecution and maintenance of Intrexon’s patents.

10


In November of 2017 the Lantibiotic ECC was amended to: (i) consolidate the development milestone payments into one payment of $25,000,000, being due six months after receiving FDA approval of a New Drug Application, (ii) reduce the sublicense revenue percentage we would have had to pay from 50% to 25% of sublicensing revenue, (iii) reduce the royalty rate from 25% of Product Profit to 10% of Net Sales, (iv) revise the form of milestone payments from being share based or cash at the Company’s election to only cash, and (v) commit that Diligent Efforts (as defined in the Lantibiotic ECC) in pursuing the Lantibiotic Program would be deemed satisfied in 2018 provided that at least $1,200,000 was budgeted for the advancement of the Lantibiotic Program.

In November of 2017, the Stock Issuance Agreement was also amended. Under the terms of the amendment, the Company has agreed to make certain payments, in cash, to Intrexon upon our achievement of designated milestones. The milestone events and amounts payable are as follows:

 

(i)

a one-time payment of twenty-five million United States dollars ($25,000,000) within six (6) months of the achievement of the Regulatory Approval Milestone Event meaning receiving approval from the FDA of a New Product Application for an Oragenics Product (or equivalent regulatory action in a foreign jurisdiction);

 

(ii)

a one-time payment of five million United States dollars ($5,000,000) within six (6) months of the achievement of the New Indication Milestone Event meaning receiving approval from the FDA of a Supplemental FDA Application (or an equivalent filing with another equivalent regulatory agency) which Supplemental FDA Application sought approval of an indication for use of the Oragenics Product other than the current regulatory-approved indication; and

 

(iii)

a one-time payment of five million United States dollars ($5,000,000) within six (6) months of the achievement of the New Product Milestone Event meaning receiving approval from the FDA of a New Product Application that is deemed to be a different drug product that the first Oragenics Product that was clinically pursued under the Lantibiotics Program.

Pursuant to the terms of the amendment, we will also pay Intrexon on a quarterly basis 10% of Net Sales derived in that quarter from the sale of products developed from the Lantibiotic ECC, calculated on an Oragenics Product-by-Oragenics Product basis and we will pay Intrexon on a quarterly basis 25% of revenue obtained in that quarter from a sublicensor in the event of a sublicensing arrangement.

On July 21, 2016, the Lantibiotics ECC was amended to revise the definition of Field in view of a provisional patent application filing between Intrexon and Oragenics and to further clarify Oragenics’ rights under the Lantibiotic ECC to genetically modified Streptococcus mutans that express Lantibiotic(s).

None of the Lantibiotic ECC milestones had been achieved as of June 30, 2019.

The Oral Mucositis ECC

Under the Oral Mucositis ECC, and subject to certain exceptions, the Company is responsible for, among other things, funding the further anticipated development of products toward the goal of commercialization, conducting preclinical and clinical development of candidate products, as well as for other aspects of manufacturing and the commercialization of the product(s). Among other things, Intrexon is responsible for technology discovery efforts, cell-engineering development, and certain aspects of the manufacturing process.

In November of 2017 the Company amended the Oral Mucositis ECC to: (i) consolidate the development milestone payments into one payment of $27,500,000 being due within six months after receiving FDA approval of a New Product Application; (ii) reduce the sublicense revenue percentage from 50% to 25% of sublicensing revenue; and (iii) revise the field in which the Company has exclusive rights to its Oral Mucositis product candidate for the treatment of Oral Mucositis to clarify that the Company has an exclusive for the treatment of Oral Mucositis in humans regardless of etiology.

Pursuant to the terms of the Oral Mucositis ECC, as amended, we are obligated to pay Intrexon on a quarterly basis 12% of the net sales derived from the sale of products developed from the exclusive channel collaboration. We are also obligated to pay Intrexon on a quarterly basis, 25% of revenue obtained in that quarter from a sublicensor in the event of a sublicensing arrangement.

11


In November of 2017, the Stock Issuance Agreement and Oral Mucositis ECC were amended. Under the terms of the amendment, the Company has agreed to make certain payments to Intrexon upon our achievement of designated milestones in the form of shares of our Common Stock (based upon the fair market value of the shares otherwise required to be issued) unless the issuance of such shares would reasonably likely cause Intrexon to consolidate our financial statements with Intrexon’s financial statements, or at our option make a cash payment to Intrexon. The milestone events and amounts payable are as follows:

 

(i)

a one-time payment of twenty-seven million five hundred thousand United States dollars ($27,500,000) within six (6) months of the achievement of the Regulatory Approval Milestone Event meaning receiving approval from the FDA of a New Product Application for an Oragenics Product (or equivalent regulatory action in a foreign jurisdiction);

 

(ii)

a one-time payment of five million United States dollars ($5,000,000) within six (6) months of the achievement of the New Indication Milestone Event meaning receiving approval from the FDA of a Supplemental FDA Application (or an equivalent filing with another equivalent regulatory agency) which Supplemental FDA Application sought approval of an indication for use of the Oragenics Product other than the current regulatory-approved indication; and

 

(iii)

a one-time payment of five million United States dollars ($5,000,000) within six (6) months of the achievement of the New Product Milestone Event meaning receiving approval from the FDA of a New Product Application that is deemed to be a different drug product that the first Oragenics Product that was clinically pursued under the Program.

None of the Oral Mucositis ECC milestones had been achieved as of June 30, 2019.

The Oral Mucositis ECC provides that in the event (i) Oragenics is required to make a milestone payment in cash as an issuance of shares would cause Intrexon to consolidate the Company’s financial statements with Intrexon’s financial statements, and (ii) Oragenics reasonably concludes that a cash milestone payment would have an adverse effect on its working capital needs over the next twelve (12) months, then such cash payment shall be in the form of an interest bearing promissory note with a maturity date of less than twelve (12) months and include other conventional market terms that would not be expected to unreasonably have an adverse effect on Oragenics working capital needs over such twelve (12) month period.

Leases

The Company’s Alachua facility is being leased from a real estate developer for a term of five years beginning in December 2014. Under the lease agreement, the rental payments range from $9,641 per month to $10,851 per month. In June of 2019, the Company entered into an amendment for the Alachua facility for a term of five years beginning in December of 2019. Under the amended lease agreement, the rental payments range from $12,870 per month to $13,338 per month. The lease may be terminated prior to its stated expiration date upon the payment of nine-months rent.

In November of 2016, the Company entered into an amendment for the leased office space for corporate personnel located in Tampa, FL. The amended lease is for approximately 2,207 square feet. The lease period for the office space is for thirty-six months commencing on March 1, 2017. Lease payments range from $4,138 per month to $4,392 per month inclusive of insurance, taxes and utilities. The lease expires on February 29, 2020.

Supplemental balance sheet information related to leases is as follows:

 

 

June 30, 2019

 

Operating lease right-of-use assets

 

$

756,337

 

 

 

 

 

 

Operating lease liabilities - Short term

 

$

140,327

 

Operating lease liabilities - Long term

 

 

616,157

 

Total operating lease liabilities

 

$

756,484

 

 

 

 

 

 

Weighted Average Remaining Lease Term In Years

 

 

 

 

Operating leases

 

 

4.22

 

 

 

 

 

 

Weighted Average Discount Rate

 

 

 

 

Operating leases

 

 

5.65

%

12


Maturities of operating lease liabilities are as follows:

Year ended December 31:

 

 

 

 

2019

 

$

93,476

 

2020

 

 

163,224

 

2021

 

 

154,908

 

2022

 

 

160,056

 

2023

 

 

160,056

 

2024

 

 

146,717

 

Total

 

$

878,437

 

  Less: Imputed interest

 

 

(121,953

)

Present value of lease liabilities

 

$

756,484

 

The cost component of operating leases is as follows:

 

 

For the Six Months

Ended June 30, 2019

 

Operating lease cost

 

$

99,320

 

Short-term lease cost

 

 

3,822

 

Total lease cost

 

$

103,142

 

Supplemental cash flow information related to operating leases is as follows:

 

 

For the Six Months

Ended June 30, 2019

 

Cash paid for amounts included in the measurement of lease liabilities:

 

 

 

 

  Operating cash flows from operating leases

 

$

99,467

 

 

8. Related Party Transactions

During the three and six months ended June 30, 2019, we paid $77,704 and $117,311; and during the three and six months ended June 30, 2018, we paid $89,216 and $159,233, respectively, to Intrexon under the Oral Mucositis ECC and Lantibiotic ECC agreements (See Note 7). Included in accounts payable and accrued expenses at June 30, 2019 and December 31, 2018 was $47,448 and $39,607, respectively, related to unpaid invoices received from Intrexon relating to work performed under the ECC Agreements. As of June 30, 2019 and 2018 Intrexon beneficially owned approximately 3.36% and 25.4% of our outstanding common stock excluding Intrexon’s ownership of our Series C Preferred which has no voting rights. In addition, during the first quarter of 2019, we paid a dividend on Series C Preferred Stock in the form of Series C Preferred Stock, to Intrexon as the sole holder of such preferred stock, pursuant to the terms of such Series C Preferred Stock (See Note 9 Shareholders’ Equity—Preferred Stock).

Dr. Frederick Telling, Chairman and Director, and Dr. Alan Joslyn, Chief Executive Officer and President, participated in the Company’s, March 25, 2019, underwritten public offering, (See Note 9 Shareholders’ Equity—Common Stock), through the purchase of 100,000 shares and 66,667 shares, respectively, of the Company’s common stock and short-term warrants to purchase 50,000 shares and 33,333 shares, and long-term warrants to purchase 50,000 shares and 33,333 shares respectively, of the Company’s common stock. Dr. Telling’s and Dr. Joslyn’s participation in the offering was approved by the Company’s Audit Committee.

13


9. Shareholders’ Equity

Common Stock

Closing of Underwritten Public Offering

On March 25, 2019, the Company announced the closing of an underwritten public offering for gross proceeds of approximately $12.5 million, which included the partial exercise of the underwriter’s over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company.

The offering was comprised of 16,666,668 shares of common stock, together with short-term warrants to purchase up to 8,333,334 shares of common stock, and long-term warrants to purchase up to 8,333,334 shares of common stock, at a price to the public of $0.75. The Company granted the underwriter a 30-day option to purchase up to 2,500,000 additional shares of common stock and/or short-term warrants to purchase 1,250,000 shares of common stock and long-term warrants to purchase 1,250,000 shares of common stock of the Company at the public offering price, less underwriting discounts and commissions. The underwriter did not exercise its option to purchase additional shares of common stock, however the underwriter exercised its option to purchase the short-term warrants to purchase 1,250,000 shares of common stock and long-term warrants to purchase 1,250,000 shares of common stock effective as of the closing.

Each short-term warrant has an exercise price of $0.75 per share of common stock, is immediately exercisable, and will expire on the earlier of (1) the eighteen-month anniversary of the date of issuance and (2) twenty-one trading days following the Company’s release of top-line data related to its Phase 2 double blind, placebo controlled clinical trial of AG013. Each long-term warrant has an exercise price of $0.90 per share of common stock, is immediately exercisable and will expire five years following the date of issuance.

The Company intends to use the net proceeds of the offering to fund its AG013 research, clinical trials, pre-clinical development of the lantibiotics program, and for working capital and general corporate purposes.

Other Share Issuance

On February 1, 2019, and May 1, 2019, respectively, the Company issued 12,500 shares of its common stock as partial consideration for the acquisition of certain services.

Preferred Stock

Series C Non-Voting, Non- Convertible Preferred Stock Financing Intrexon Debt Conversion

Each issued and outstanding share of Series C Preferred Stock entitled the holder of record, Intrexon, to receive dividends at the annual rate of twelve percent (12%) (the “Initial Rate”) of its Stated Value, payable by issuing additional shares of Series C Preferred Stock within thirty days after the end of each calendar year pro-rata for partial years. The Initial Rate was automatically increased to twenty percent (20%) after May 10, 2019. In January of 2019 we issued 12.208 shares of the Company’s Series C Preferred Stock as a dividend to Intrexon, as the holder of the Series C Preferred Stock.

14


Changes In Shareholders’ Equity

A summary of the changes in shareholders’ equity for the three and six months ended June 30, 2019 and 2018 is as follows:

 

 

 

Common Stock

 

 

Preferred Stock

 

 

Additional

 

 

 

 

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Paid In

 

 

Accumulated

 

 

Shareholders’

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Equity

 

Balances at December 31, 2018

 

 

29,433,135

 

 

$

29,433

 

 

 

16,017,101.733

 

 

$

6,100,182

 

 

$

126,125,976

 

 

$

(111,373,608

)

 

$

20,881,983

 

Compensation expense

   relating to option issuances

 

 

 

 

 

 

 

 

 

 

 

 

 

 

145,829

 

 

 

 

 

 

145,829

 

Issuance of common stock -

   shelf takedown, net of expenses

 

 

16,666,668

 

 

 

16,667

 

 

 

 

 

 

 

 

 

11,399,009

 

 

 

 

 

 

11,415,676

 

Issuance of common stock

   in exchange for services

 

 

12,500

 

 

 

12

 

 

 

 

 

 

 

 

 

5,988

 

 

 

 

 

 

6,000

 

Series C dividend

 

 

 

 

 

 

 

 

12.208

 

 

 

413,214

 

 

 

 

 

 

(413,214

)

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(3,325,717

)

 

 

(3,325,717

)

Balances at March 31, 2019

 

 

46,112,303

 

 

$

46,112

 

 

 

16,017,113.941

 

 

$

6,513,396

 

 

$

137,676,802

 

 

$

(115,112,539

)

 

$

29,123,771

 

Compensation expense

   relating to option issuances

 

 

 

 

 

 

 

 

 

 

 

 

 

 

164,588

 

 

 

 

 

 

164,588

 

Issuance of common stock -

   shelf takedown, net of expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(65,000

)

 

 

 

 

 

(65,000

)

Issuance of common stock

   in exchange for services

 

 

12,500

 

 

 

13

 

 

 

 

 

 

 

 

 

5,988

 

 

 

 

 

 

6,001

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(4,806,460

)

 

 

(4,806,460

)

Balances at June 30, 2019

 

 

46,124,803

 

 

$

46,125

 

 

 

16,017,113.941

 

 

$

6,513,396

 

 

$

137,782,378

 

 

$

(119,918,999

)

 

$

24,422,900

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common Stock

 

 

Preferred Stock

 

 

Additional

 

 

 

 

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Paid In

 

 

Accumulated

 

 

Shareholders’

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Equity

 

Balances at December 31, 2017

 

 

4,928,335

 

 

$

4,928

 

 

 

18,600,100.000

 

 

$

6,309,608

 

 

$

101,402,570

 

 

$

(101,400,797

)

 

$

6,316,309

 

Compensation expense

   relating to option issuances

 

 

 

 

 

 

 

 

 

 

 

 

 

 

118,324

 

 

 

 

 

 

118,324

 

Conversion of Series A preferred

   stock to common stock

 

 

258,300

 

 

 

259

 

 

 

(2,583,000

)

 

 

(268,096

)

 

 

267,837

 

 

 

 

 

 

 

Series C dividend

 

 

 

 

 

 

 

 

1.733

 

 

 

58,670

 

 

 

 

 

 

(58,670

)

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(2,119,397

)

 

 

(2,119,397

)

Balances at March 31, 2018

 

 

5,186,635

 

 

$

5,187

 

 

 

16,017,101.7330

 

 

$

6,100,182

 

 

$

101,788,731

 

 

$

(103,578,864

)

 

$

4,315,236

 

Compensation expense

   relating to option issuances

 

 

 

 

 

 

 

 

 

 

 

 

 

 

81,986

 

 

 

 

 

 

81,986

 

Issuance of common stock -

   shelf takedown, net of expenses

 

 

900,000

 

 

 

900

 

 

 

 

 

 

 

 

 

1,509,427

 

 

 

 

 

 

1,510,327

 

Issuance of restricted

   common stock

 

 

16,000

 

 

 

16